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SUMMARY
Background
Chronic intestinal pseudo-obstruction is a disabling condition for which
there are no established drug therapies. The condition is caused by a
diverse range of intestinal myopathies and neuropathies.
Aim
To assess the therapeutic efﬁcacy of prucalopride, a selective high-afﬁnity
5-HT4 receptor agonist, we employed a multiple n = 1 study design. Each
patient acted as his⁄her own control, each day counting as one treatment
episode, allowing comparison of 168 days on each of active drug and
placebo.
Methods
Double-blind, randomised, placebo-controlled, cross-over trial of four 12-
week treatment periods, with 2–4 mg prucalopride or placebo daily. In each
of the ﬁrst and second 6 months there was a prucalopride and a placebo
treatment. Patients with proven chronic intestinal pseudo-obstruction,
including dilated gut, were included. Evaluation was by patient diary and
global evaluation.
Results
Seven patients participated (mean 42 years, ﬁve female, median symptom
duration 11 years). Three discontinued, two due to study length, and one
on prucalopride due to unrelated malnutrition and bronchopneumonia.
Four patients (three visceral myopathy and one visceral neuropathy) com-
pleted the study; prucalopride signiﬁcantly improved pain in three of four
patients, nausea in two, vomiting in one, bloating in four and analgesic
intake. Bowel function was not changed substantially.
Conclusions
n = 1 studies in rare conditions allow drug efﬁcacy assessment. Prucalopride
relieves symptoms in selected patients with chronic pseudo-obstruction.
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The term chronic idiopathic intestinal pseudo-obstruc-
tion (CIP) denotes a clinical syndrome of apparent bowel
obstruction in the absence of an obstructing lesion. The
term ‘pseudo-obstruction’ was ﬁrst used to describe a
cohort of patients with recurrent vomiting, abdominal
pain and distension, who had undergone repeated lapa-
rotomy with no obstructive cause demonstrated.
1 The
symptoms relate in part to the failure of intestinal pro-
pulsion, due to an underlying disorder of enteric nerves
or muscle.
The underlying pathology of this condition is hetero-
geneous, encompassing a range of visceral myopathies
and neuropathies.
2–4 The gut pathology may be primary
(idiopathic) or secondary to a more widespread systemic
disease of a degenerative, inﬂammatory, ischaemic or
autoimmune nature.
The condition is rare with a wide spectrum of sever-
ity. It is sometimes diagnosed in the setting of abnormal
gut motor function and pain without gut morphological
change.
5, 6 The diagnosis is deﬁnite when the gut is
dilated, there is no obstructing lesion, and gut pathology
has been established.
At present, there are no drug therapies proven in con-
trolled trials to improve gut function or symptoms in
this condition. Abdominal pain is a major symptom for
many patients, and some ultimately require regular opi-
ate analgesia. Nausea, vomiting and distension are almost
invariable, culminating in the majority of patients requir-
ing nutritional support. In many, the severity of symp-
toms leads with time to the need for home-based
parenteral nutrition.
3 The prokinetic, cisapride, has been
studied in patients with CIP, and was modestly better
than placebo in improving symptoms in adults.
7 In an
uncontrolled study, erythromycin, a motilin analogue,
caused a decrease in vomiting and improved bowel func-
tion in some patients with primary and secondary CIP.
8
Prucalopride, a substituted benzamide with selective
5HT4-agonist activity has been shown previously to
improve symptoms in patients with idiopathic constipa-
tion, accelerating both upper and lower gut transit.
9–11 A
recent multi-centre randomised placebo-controlled study
has shown that the drug improves bowel function and
symptom burden in severe chronic constipation.
12 The
drug is well tolerated, with no signiﬁcant increase in the
number adverse effects compared with placebo.
10, 13
Most recently, prucalopride has been approved in Eur-
ope for the symptomatic treatment of chronic constipa-
tion in women in whom laxatives fail to provide
adequate relief.
The present study aimed to evaluate the efﬁcacy and
safety of prucalopride, in a once daily dose of 2–4 mg, in
patients with known CIP. It was felt that, given the rarity
of the condition and the diversity of the underlying
pathology, it would not be possible to undertake a stan-
dardised parallel-group, placebo-controlled study. A par-
allel group study may also have obscured beneﬁt for
patients with some subtypes of pathology, while the
group as a whole has a diversity of underlying patholo-
gies which may respond differently to active treatment.
The chronic and ﬂuctuating nature of symptoms also
means that any study needs to be performed over a long
enough time period to demonstrate a difference between
active treatment and placebo. To overcome these prob-
lems, we chose to undertake an ‘n = 1’, placebo-con-
trolled study in which individual patients acted as their
own controls. Patients were studied over 48 weeks,
receiving either prucalopride or placebo given once a day
for four randomised periods of 12 weeks.
MATERIALS AND METHODS
Trial design
We undertook a single-centre, randomised, double-blind,
placebo-controlled, cross-over study in subjects with deﬁ-
nite, established CIP. Patients were treated for periods of
12 weeks with either placebo or prucalopride once daily.
Subject numbers were assigned in consecutive order and
the following four sequences were used: ABAB, BABA,
ABBA and BAAB (A = placebo, B = prucalopride).
Active treatment consisted of a single 2 mg tablet of pru-
calopride. If patients felt one tablet was not providing
symptomatic relief, they could increase to two tablets
according to subjective response and after conﬁrmation
with the investigators. If they experienced side-effects,
down titration back to one tablet was allowed. In each of
the ﬁrst and second 6 month periods there was one pla-
cebo and one active drug treatment period. There were
no wash-out periods. Study visits took place at weeks 0,
4, 12, 16, 24, 36 and 48 of treatment. Patients kept a
daily symptom diary to collect daily symptom severity
scores.
Patients
Seven patients (ﬁve female, median age 39) were enrolled
into the study. They had long-standing, deﬁnite CIP with
a median duration of illness of 137 months. To be
included, patients had to have had episodic obstructive
symptoms and radiological evidence of small bowel dila-
tation, in the proven absence of obstructing pathology.
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ing gut pathology: four patients had primary visceral
neuropathy, two had primary visceral myopathy, and
one had visceral myopathy secondary to scleroderma. All
subjects were on stable doses of medication for their
CIP. If the subject was already taking a prokinetic drug
this could be continued, recording daily intake in the
trial diary. Subjects could not, however, start on new
medication during the study. Table 1 shows the clinical
data.
The study was approved by the Northwick Park
and St Mark’s Ethics Committee. All subjects gave
written informed consent to participate in the study.
Trial registration number: ClinicalTrials.gov NCT007
93247.
Efﬁcacy
Patients recorded the following data on a daily basis in
their diary:
(i) Intake of medication.
(ii) Time of bowel emptying.
(iii) Consistency of stools (watery, paste, normal, hard
or very hard).
(iv) Time of intake of laxatives and analgesics.
(v) Intake and amount of erythromycin.
(vi) The occurrence and severity of each of four
symptoms: pain, nausea, vomiting and bloating, each
scored as 0 = absent, 1 = mild, 2 = medium, 3 = severe,
or 4 = could not be worse.
(vii) The ability to eat food and ﬁnish a meal
(yes⁄no).
Safety and adverse events
Patients recorded any adverse effects in their daily diary,
and reported any to the investigator. The investigator
determined how likely it was that the reported adverse
effect was related to study medication. Due to the nature
of CIP, it was almost inevitable that patients would be
admitted to hospital during the course of a 1-year study.
Admissions for severe episodes of CIP were noted, but
not reported as adverse events.
Blood samples for biochemistry, haematology and uri-
nalysis, were performed at weeks 0 and 24. Blood pres-
sure, heart rate and ECG were assessed at week 0 and 24.
Statistical analysis
As a multiple n = 1 study, descriptive statistics and
graphical visualisation of results for each patient over
time were considered as most important for the evalua-
tion of efﬁcacy and safety parameters. For each patient
these data of the different 12 week treatment periods
were summarised per treatment: placebo or prucalopride
analysed as the total for each period of 12 weeks.
The primary endpoint was the proportion of days that
each of the main symptoms was present (i.e. score >0).
Secondary end-points included the mean score for each
symptom. The primary comparison was always a within-
subject comparison of results during treatment with pru-
calopride vs. results during placebo treatment. For each
subject, the Wilcoxon rank sum test was used to compare
the daily symptoms severity scores during prucalopride
treatment with the scores during placebo treatment.
RESULTS
Patients
Seven patients (four visceral neuropathy and three vis-
ceral myopathy) entered the study. Three patients, all
with visceral neuropathy, discontinued treatment shortly
after the ﬁrst treatment period: one due to serious
adverse events believed to be unrelated to the study med-
ication (feeding line infection, sepsis, bronchopneumonia
and malnutrition), and two due to withdrawal of consent
(one each on placebo and prucalopride) as the individu-
als felt unable to comply with maintaining a daily diary.
The other four subjects (three visceral myopathy and
one visceral neuropathy) completed the four treatment
periods and had sufﬁcient symptom scores available for
evaluation of efﬁcacy.
Table 2 shows the treatment details for each subject.
Of patients completing the study, three used mainly a
daily dose of 2 mg, and one patient used a daily dose of
Table 1 | Patient demographics
Parameter All patients (n =7 )
Number
Sex
Female 5
Male 2
Primary disease
Visceral myopathy 3
Visceral neuropathy 4
Median (Min; Max)
Age, years 39 (28; 68)
Body mass index 21.7 (17.5; 23.6)
Weight, kg 50 (42; 68)
Time since onset of symptoms, months 137 (80; 160)
A A. . V V. . E Em mm ma an nu ue el l e et t a al l. .
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periods.
Efﬁcacy parameters
Symptom evaluations. Figure 1 and Table 3 show the
distribution of the proportion of days with and without
symptoms (pain, vomiting, nausea and bloating) for each
of the four patients who completed the study, during
placebo- and prucalopride- treatment days. One subject
(3006) reported very few days with the presence of
symptoms during both placebo and prucalopride treat-
ment, hence there was little room for improvement. All
the other subjects showed an improvement in at least
one of the symptoms with active treatment.
Bloating improved in all subjects, with both the fre-
quency and average severity decreasing with prucalopride
in all subjects (Table 3). Vomiting was present in two
subjects, with the average severity decreasing in both,
and the frequency decreasing in one.
Symptoms changed in both frequency (Fig. 1) and
severity (Fig. 2) with active treatment. Figure 2 shows
all symptom severity scores for each patient, on
prucalopride and placebo. Changes in symptom fre-
quency did not always mirror changes in severity. For
example in one patient (3002), whose treatment
sequence was placebo-prucalopride-prucalopride-pla-
cebo, pain was reported for all days throughout the
study (Fig. 1), but pain severity decreased signiﬁcantly
with prucalopride compared with placebo treatment
(Table 3, Fig. 2).
Prucalopride did not affect the mean weekly stool fre-
quency and consistency, the pattern of laxative use, the
percentage of days able to eat food and ﬁnish a meal,
and the number of periods of more than 24 h without a
stool per 4 weeks.
Rescue analgesia use. Two subjects used on-demand
(rescue) analgesia during the study. For both subjects,
the number of analgesia intakes decreased substantially
during treatment with prucalopride compared with the
placebo periods (Table 4).
Body weight. Body weight was stable for all four patients
during the course of the yearlong study.
Table 2 | Treatment details
Patient Phase Treatment
Mean daily dose, mg
(Inclusive days off drug)
Treatment
duration, days
A03001 (vn) Period 1 Pru 3 99
A03002 (vm) Period 1 Pla 0 82
Period 2 Pru 1.42 68
Period 3 Pru 2 83
Period 4 Pla 0 117
A03003 (vn) Period 1 Pla 0 75
A03004 (vn) Period 1 Pru 2 85
Period 2 Pla 0 28
A03005 (vn) Period 1 Pla 0 92
Period 2 Pru 1.6 47
Period 3 Pru 2 75
Period 4 Pla 0 92
A03006 (vm) Period 1 Pla 0 99
Period 2 Pru 3 91
Period 3 Pla 0 98
Period 4 Pru 3 85
A03007 (vm) Period 1 Pru 2 86
Period 2 Pla 0 70
Period 3 Pru 2 85
Period 4 Pla 0 85
Pla, Placebo; Pru, Prucalopride; vm, visceral myopathy; vn, visceral neuropathy.
R Ra an nd do om mi is se ed d c cl li in ni ic ca al l t tr ri ia al l: : p pr ru uc ca al lo op pr ri id de e i in n c ch hr ro on ni ic c i in nt te es st ti in na al l p ps se eu ud do o- -o ob bs st tr ru uc ct ti io on n
Aliment Pharmacol Ther 2012; 35: 48–55 51
ª 2011 Blackwell Publishing Ltd(b) (d) Bloating Nausea
* * *
80%
100%
60%
40%
20%
0%
3
0
0
2
 
p
l
a
3
0
0
6
 
p
l
a
3
0
0
2
 
p
r
u
3
0
0
6
 
p
r
u
3
0
0
7
 
p
l
a
3
0
0
7
 
p
r
u
3
0
0
5
 
p
r
u
3
0
0
5
 
p
l
a
3
0
0
2
 
p
l
a
3
0
0
6
 
p
l
a
3
0
0
2
 
p
r
u
3
0
0
6
 
p
r
u
3
0
0
7
 
p
l
a
3
0
0
7
 
p
r
u
3
0
0
5
 
p
r
u
3
0
0
5
 
p
l
a
(a)
80%
100%
Pain
* *
60%
40%
20%
0%
3
0
0
2
 
p
l
a
3
0
0
6
 
p
l
a
3
0
0
2
 
p
r
u
3
0
0
6
 
p
r
u
3
0
0
7
 
p
l
a
3
0
0
7
 
p
r
u
3
0
0
5
 
p
r
u
3
0
0
5
 
p
l
a
(c) Vomiting
* *
3
0
0
2
 
p
l
a
3
0
0
6
 
p
l
a
3
0
0
2
 
p
r
u
3
0
0
6
 
p
r
u
3
0
0
7
 
p
l
a
3
0
0
7
 
p
r
u
3
0
0
5
 
p
r
u
3
0
0
5
 
p
l
a
80%
100%
60%
40%
20%
0%
80%
100%
60%
40%
20%
0%
Figure 1 | Proportion of days
with symptoms (dark) vs. no
symptoms (light) for (a) pain,
(b) nausea, (c) vomiting and
(d) bloating for each of the
four patients completing the
study. Each number (pair of
bars) represents a different
patient, for whom all days on
placebo and active drug have
been summed. *Statistically
signiﬁcant reduction
(P < 0.05) of symptoms with
prucalopride vs. placebo. Pru,
Prucalopride; Pla, Placebo.
Table 3 | Mean symptom severity score for each of the four patients completing the study
Patient
Symptom
Pain Vomiting Nausea Bloating
PLA PRU PLA PRU PLA PRU PLA PRU
A03002 vm N (days) 176 142 169 142 170 142 171 141
Mean 1.6 1.4 0.3 0.2 0.7 0.2 1.5 1.3
s.d. 0.63 0.55 0.97 0.52 1.08 0.61 0.73 0.5
P-value <0.0001 0.7351 <0.0001 0.0092
A03005 vn N (days) 170 119 168 118 168 118 168 118
Mean 0.9 0.7 0 0 0 0 0.1 0
s.d. 0.68 0.72 0 0 0.08 0 0.27 0.09
P-value 0.0391 1.000 0.4060 0.0080
A03006 vm N (days) 182 167 182 167 182 167 182 166
Mean 0.1 0 0 0 0 0 0.1 0
s.d. 0.35 0.17 0 0 0 0.08 0.31 0.08
P-value 0.1656 1.000 0.2999 <0.0001
A03007 vm N (days) 146 163 141 161 146 161 143 160
Mean 2.2 0.8 1.0 0.1 2.0 0.7 1.5 0.4
s.d. 1.4 1.19 1.42 0.48 1.3 0.99 1.47 0.8
P-value <0.0001 <0.0001 <0.0001 <0.0001
vm, visceral myopathy; vn, visceral neuropathy; s.d., standard deviation.
(0 = absent, 1 = mild, 2 = medium, 3 = severe, 4 = could not be worse).
A A. . V V. . E Em mm ma an nu ue el l e et t a al l. .
52 Aliment Pharmacol Ther 2012; 35: 48–55
ª 2011 Blackwell Publishing LtdAdverse events
Three patients reported adverse events. One patient
reported this during placebo treatment only. Another
patient reported adverse effects during placebo and pru-
calopride treatment periods, and another during one
prucalopride treatment period only.
All but one adverse event were experienced as severe,
but none were judged by the investigator to be drug-
related. The commonest complaints were of abdominal
pain, constipation and vomiting.
One subject permanently stopped the trial medication
and prematurely discontinued the trial due to an episode
100
(a)
(b)
(c)
Pain
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Vomiting
80
60
40
20
0
PLA PRU
A03002
Absent Mild Medium Severe Could not be worse
Absent Mild Medium Severe Could not be worse
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(d) Bloating
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Figure 2 | Proportion of days
with each symptom severity
score for (a) pain, (b) nausea,
(c) vomiting and (d) bloating.
Each pair of bars represents a
different patient, for whom all
days on placebo and active
drug have been summed –
168 days on each of prucalo-
pride and placebo treatments.
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her death 2 months after the last intake of drug.
No clinically relevant observations were made in clini-
cal laboratory parameters, vital signs or electrocardio-
grams. Speciﬁcally there were no changes in QT duration
with prucalopride treatment.
DISCUSSION
A large number of studies have demonstrated previously
that prucalopride is effective in relieving symptoms in
patients with chronic constipation.
11–15 In particular,
prucalopride increases bowel frequency and reduces
abdominal bloating and pain.
11 This study has shown
that in some patients with chronic intestinal pseudo-
obstruction prucalopride is effective in alleviating symp-
toms. To our knowledge this is the ﬁrst long-term, dou-
ble-blind, placebo-controlled, randomised study to show
therapeutic beneﬁt from medication in this disabling
condition. Speciﬁcally, it was most effective in relieving
the symptom of bloating. There are few, if any, options
for managing this symptom.
16 Prucalopride was also
shown to be effective in reducing abdominal pain and
nausea. Prucalopride reduced the frequency and severity
of these symptoms.
Prucalopride is a potent, highly-selective 5HT4 agonist
with no 5HT3 antagonism and no anticholinergic activ-
ity.
17 It enhances peristalsis and accelerates colonic tran-
sit.
10, 18–20 Prucalopride also accelerates small bowel
transit in animals and humans.
10, 11, 18 As such, prucalo-
pride is a potentially beneﬁcial agent in patients with
CIP, where small and large bowel motility are perturbed.
Doses of 1–4 mg of prucalopride have been shown to be
effective in relieving the symptoms of constipation.
11, 12
Given the severity of the condition, we chose to use a
dose of 2–4 mg per day in this study.
An n = 1 cross-over study design potentially establishes
the beneﬁcial effects of a drug in an individual, in contrast
to parallel-group studies which establish efﬁcacy in a
group of patients with a common condition.
21 Given the
ﬂuctuating nature of symptoms in CIP it was important to
have a long enough period of observation on both active
drug and placebo. We reasoned that a 6-month exposure
to each would permit this, spread over a year, with a
randomised alternation between active drug and placebo.
An example of the impact of a single individual affect-
ing the data set in a traditional group placebo-controlled
study vs. their impact in an n = 1 study, such as this one,
can be drawn from the symptoms experienced by patient
3006. This patient experienced major frequent symptoms
in the year prior to entering this study, but few symptoms
during the year of the study. This patient would have
diluted the therapeutic assessment in a traditional study.
Prucalopride did not affect stool frequency and consis-
tency. None of the four patients showed evidence of a
major prokinetic effect on gastrointestinal transit. How-
ever, prucalopride did have an effect on gut sensory
symptoms, improving nausea and pain. We have previ-
ously shown that prucalopride heightens visceral sensa-
tion to both distension and mucosal electric stimulation
in patients with chronic constipation.
11
Three subjects reported adverse events, but none were
judged by the investigator, who was blind to the phase
of treatment, to be related to study medication. Equally,
no signiﬁcant changes in haematology or biochemistry
were identiﬁed following 6 months exposure to prucalo-
pride. No electrocardiographical changes were seen, sup-
porting previous studies showing that, unlike some other
serotonergic compounds, prucalopride does not cause re-
polarisation changes.
In summary, prucalopride represents a potentially use-
ful novel therapy for some patients with chronic intesti-
nal pseudo-obstruction. The main beneﬁt related to the
relief of bloating and abdominal pain. The drug is well
tolerated in this condition.
Table 4 | Average weekly number of analgesia intakes per week in the two patients who used on-demand (rescue)
analgesia during the study
Patient Treatment
Analgesia
Number of
intakes
Number of days
with intakes
Average intakes⁄
week (s.d.)
P-value
(t-test)
A03002 Placebo 412 195 14.8 (11.03) <0.001
Prucalopride 211 169 8.7 (3.31)
A03007 Placebo 370 149 17.4 (10.21) <0.001
Prucalopride 229 166 9.7 (6.24)
s.d., standard deviation.
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